The European Union (EU) has approved Enhertu, a collaboration drug by AstraZeneca and Daiichi, for the treatment of  breast cancer.

The approval was announced on Tuesday, for adult patients with an aggressive form of breast cancer.

AstraZeneca said that Enhertu could be used as a monotherapy in cases with unresectable or metastatic HER2-positive breast cancer.

The  drug was jointly developed and commercialized by AstraZeneca and Daiichi Sankyo. it was certified by the European Medicines Agency (EMA) in June.

EMA said Enhertu was effective at shrinking the tumour in patients with metastatic breast cancer or breast cancer that could not be removed by surgery.